{"name":"Acacia Research","slug":"acacia","ticker":"ACTG","exchange":"NASDAQ","domain":"acaciaresearch.com","description":"Acacia Research Corporation is a publicly traded American company based in New York City. It acquires and operates businesses in industries including the technology, energy, and industrial/manufacturing sectors. Acacia has a strategic relationship with Starboard Value, LP, the company's controlling shareholder. The company has been characterized as a patent troll.","hq":"Dallas, TX","founded":0,"employees":"986","ceo":"MJ McNulty","sector":"IP Licensing / Life Sciences","stockPrice":5.13,"stockChange":0,"stockChangePercent":0,"marketCap":"$495M","metrics":{"revenue":12004000,"revenueGrowth":2.6,"grossMargin":29.6,"rdSpend":37000,"netIncome":21682000,"cash":361020000,"dividendYield":0,"peRatio":23.3,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2020-01-01","label":"Barhemsys first approved","drug":"Barhemsys","drugSlug":"amisulpride","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lovenox patent cliff ($1.4B at risk)","drug":"Lovenox","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Effient patent cliff ($1.1B at risk)","drug":"Effient","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Barhemsys","genericName":"AMISULPRIDE","slug":"amisulpride","indication":"Prevention of PONV","status":"marketed"}]}],"pipeline":[{"name":"Barhemsys","genericName":"AMISULPRIDE","slug":"amisulpride","phase":"marketed","mechanism":"Barhemsys works by blocking dopamine receptors in the brain.","indications":["Prevention of PONV","Treatment of PONV"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Acacia Research Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Acacia Research reported its fourth quarter and full year 2023 financial results, with revenue of $13.4 million and net income of $2.3 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Acacia Research Announces Settlement of Patent Dispute with Generic Pharmaceutical Company","summary":"Acacia Research announced a settlement of a patent dispute with a generic pharmaceutical company, resolving a lawsuit over the company's patent for a generic version of a popular pharmaceutical product.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPb3FGWFVWdUhNYUcwTk00ek1KSTdVR2lnNGgxRGVHcUVKV21iNWRVbW5jUmpYaDdCaWFtQVZHV1RGdUVBajdPajhFclB4YTZja0FvSUVGX0hrUVpqUUFMTmRjNGFaaEN2UFBmbjUzSDVSOU5RaXJ6Z0dQbUMzR0hQcnZGa0draXQ3VXJfQdIBjAFBVV95cUxPb3FGWFVWdUhNYUcwTk00ek1KSTdVR2lnNGgxRGVHcUVKV21iNWRVbW5jUmpYaDdCaWFtQVZHV1RGdUVBajdPajhFclB4YTZja0FvSUVGX0hrUVpqUUFMTmRjNGFaaEN2UFBmbjUzSDVSOU5RaXJ6Z0dQbUMzR0hQcnZGa0draXQ3VXJfQQ?oc=5","date":"2026-03-19","type":"deal","source":"Insider Monkey","summary":"10 High-Flying Penny Stocks to Buy - Insider Monkey","headline":"10 High-Flying Penny Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPOTB6cHE4UDBmTlZHSmJYajN6YUJ4a1pVVm5SVGV1OUdaTlZSajE3LURBWmhGbjNWaVRsYThkWXBOOUxWclZYVWRKRy1IcjY3SzNsa0lndDBnU1gzajk4THZWbGJOLUpNMkdMUTlZcmdLVWNOWW1oMXUxWHAwdUdaMVFCUGRGUHJmOHBpdHMzdFU5emJNMDFXMlNPM0tNWkNBb0VHd2ZLWndTc09McGxZSkR5SDRmZG91c0E4c08yTG0?oc=5","date":"2026-03-13","type":"pipeline","source":"The Globe and Mail","summary":"Latest US Analyst Ratings: March 12th, 2026 - The Globe and Mail","headline":"Latest US Analyst Ratings: March 12th, 2026","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPTTRnUWdnLTBoOEVhLTN5M2x0d3pRWE5aeFNQLU5PQ2hPd3Rwd3dkandrZGlodWVNa3ZuTDRTSjVGT1JfY3YzbkVWYnJvWFVZRUhaWFJicU9mUTVYS2doOWROOElMY3Y2UWU0a1VYZmRWZ0dTTm1XN1IzRG5MVW5oVV9QN25mLTRPWS00amZ1dFR3YzkxYmg3VXdpQ0diRHg2a0VCZXphcVJqUVNCcENmSl9zMnZqSDJITVZFTVZfMHU?oc=5","date":"2026-03-11","type":"earnings","source":"Stock Titan","summary":"Acacia turns $285M 2025 revenue into more cash and zero parent debt - Stock Titan","headline":"Acacia turns $285M 2025 revenue into more cash and zero parent debt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPT0c1R2lwOXpvYXRTU212SWNxenBVaTd6RWpUdXBjWE9MNGlMTzd1QXc5WENfeWFzQUNFRC1zS0V1bjBqWGV5TmNrUzV0ZENwSU9tVDlld3Y5UTE2d29EZVQzZ1BnOGUtcDV3Y0ZOVjNZWWx3UHNSeVhZWld2T3dOMm0xU2xaQ0dBUEp6YWh4QW9NcmpxcmpXNldQNUh0RXFzcTlrVVR0U1Q0V25IOWNCOA?oc=5","date":"2026-03-11","type":"earnings","source":"Seeking Alpha","summary":"Acacia Research Corporation 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:ACTG) 2026-03-11 - Seeking Alpha","headline":"Acacia Research Corporation 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:ACTG) 2026-03-11","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPalA2aU13Q05XanZiVWRXOFlfVEdrSzhIUGNvMGFJRXdpU3kwcUZwZl9aa3JSNmxjbVpLMTVzMFVYdDhkNzZ2Y2F2R1RSdThaSnF1cERxbGJmaFItVkh0MkM5WTVHTkhLcTRzUlAzT1d3X3FjZ1FOaDF2d1hOYmh3alZkaFduWnFmYkk5LVg1ZzVCbmVwaTlHZEFVZjlocDJKbHphOVljWkhiQ1J1UkpJT2M1eFp6dw?oc=5","date":"2026-02-25","type":"earnings","source":"Stock Titan","summary":"Acacia Research schedules March 11 call on Q4 and 2025 results - Stock Titan","headline":"Acacia Research schedules March 11 call on Q4 and 2025 results","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPeEtBUUVkZG9vWGs3LVVLV1JKMUZWSlJNc2VZdUJqT2RTYmVEbGJhcUJBRENUZnhyTENWcUR6VWRZRWVnbHBwcXUyUlZDTjc0cUpZN2NZdlVWNURERFQzSS0wYjVqcjY0aXF2dUhNVmxpVUE0alVKUHpUeDcyaVpGTFNwbUhoYTBNNndJVjNEZGF4XzFFRzljWVZiaUZ5TXU3QkdZQWZINjlUY2hJX3h3?oc=5","date":"2025-08-05","type":"earnings","source":"Seeking Alpha","summary":"Acacia Research: Too Cheap To Ignore, But Tread Carefully Ahead Of Earnings - Seeking Alpha","headline":"Acacia Research: Too Cheap To Ignore, But Tread Carefully Ahead Of Earnings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOSUxWdy1pU3NMM2FpdFh4ZldxWnJrN0M2OEF1VjhCb2hSUEZBQ0dYSHJQNzIxUmVJXzJBUW1zZnhxbm1kajE2Qk1YQ0wxeUdMVDZwUF9WajlaQWNoNm5pZkpCa25PcXJrRVQzQjBLZno0Vy1ocGgtbHg0bkh4SHlBUFdtTm5VeTBuY2ZVbkN4ZHoyTU03UktCcXdwSFdZNWNmWkFQQWYwOA?oc=5","date":"2024-10-31","type":"pipeline","source":"Seeking Alpha","summary":"Acacia Research: What To Make Of Latest Acquisition Announcement (NASDAQ:ACTG) - Seeking Alpha","headline":"Acacia Research: What To Make Of Latest Acquisition Announcement (NASDAQ:ACTG)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSkFVX3lxTE5zTmZlaE8tMVJvaklmRGdvOXlnMENTX1R6QzNrTUVucjNRdkNEU21ZQkM1b0RlZjFCQzM4RzJwc192eC1tbXBhQXVB?oc=5","date":"2024-02-01","type":"pipeline","source":"eToro","summary":"ACTG Stock Price | Analyst Target 6.00 & Consensus - eToro","headline":"ACTG Stock Price | Analyst Target 6.00 & Consensus","sentiment":"neutral"}],"patents":[{"drugName":"Lovenox","drugSlug":"enoxaparin","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Effient","drugSlug":"prasugrel","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["InterDigital","Ocean Tomo","RPX Corporation"],"therapeuticFocus":["Cardiovascular","Oncology"],"financials":{"source":"sec_edgar","revenue":12004000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":12004000,"period":"2021-12-31"},{"value":29782000,"period":"2020-12-31"},{"value":4383000,"period":"2020-12-31"},{"value":19466000,"period":"2020-09-30"},{"value":2118000,"period":"2020-06-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":21682000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":770956000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":5.13,"previousClose":5.13,"fiftyTwoWeekHigh":5.22,"fiftyTwoWeekLow":2.7,"fiftyTwoWeekRange":"2.7 - 5.222","fiftyDayAverage":4.38,"twoHundredDayAverage":3.76,"beta":0.45,"enterpriseValue":280124160,"forwardPE":-9.7,"priceToBook":0.91,"priceToSales":1.74,"enterpriseToRevenue":0.98,"enterpriseToEbitda":5.44,"pegRatio":0,"ebitda":51491000,"ebitdaMargin":18.1,"freeCashflow":30700500,"operatingCashflow":75242000,"totalDebt":105643000,"debtToEquity":18.1,"currentRatio":9.18,"returnOnAssets":0.5,"returnOnEquity":4.3,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":6,"targetHighPrice":6,"targetLowPrice":6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":1446595200,"insiderHeldPercent":1.4,"institutionHeldPercent":87.7,"sharesOutstanding":96475469,"floatShares":34070312,"sharesShort":1425543,"shortRatio":3.83,"shortPercentOfFloat":1.5,"epsTrailing":0.22,"epsForward":-0.53,"revenuePerShare":2.96,"bookValue":5.63,"officers":[{"age":47,"name":"Mr. Martin D. McNulty Jr.","title":"CEO, COO, Head of M&A and Director"},{"age":46,"name":"Mr. Robert  Rasamny","title":"Chief Administrative Officer"},{"age":48,"name":"Mr. Jason W. Soncini J.D.","title":"General Counsel"},{"age":46,"name":"Ms. Kirsten  Hoover","title":"Controller"},{"age":null,"name":"Mr. Michael  Zambito","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Daniel  Troy","title":"Principal"},{"age":null,"name":"Mr. George  Broadbin","title":"Managing Director"},{"age":null,"name":"Ms. Jennifer  Graff","title":"Corporate Secretary"}],"industry":"Business Equipment & Supplies","irWebsite":"http://www.acaciaresearch.com/investors_contact.htm","website":"https://www.acaciaresearch.com","phone":"332 236 8500"}}